• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

    4/29/24 4:05:00 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email

    Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue

    Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61%

    Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction

    Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025

    GeneDx to host conference call today at 4:30 p.m. ET

    STAMFORD, Conn., April 29, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2024.

    "Our strong first quarter results reflect our continued dedication to our three key organizational focuses: growing exome and genome revenue, increasing our average reimbursement rates while expanding access to testing, and meaningfully reducing our cash burn," said Katherine Stueland, Chief Executive Officer of GeneDx. "Our team's successful execution in the first quarter gives us the confidence to raise full year 2024 revenue guidance to between $235-$245 million and reiterate our expectation to reach profitability in 2025."

    First Quarter 2024 Financial Results (Unaudited)1,2

    Revenues

    • Revenues from continuing operations grew to $61.5 million, an increase of 51% year-over-year and 6% sequentially.
      • Total company revenues were $62.4 million.
    • Exome and genome test revenue grew to $44.0 million, an increase of 96% year-over-year and 12% sequentially.

    Exome and genome volume

    • Exome and genome test results volume grew to 16,592, an increase of 91% year-over-year and 6% sequentially.
    • Exome and genome represented 30% of all test results, up from 16% in the first quarter of 2023 and up from 27% in the fourth quarter of 2023.

    Gross margin

    • Adjusted gross margin from continuing operations expanded to 61%, up from 34% in the first quarter of 2023 and up from 56% in the fourth quarter of 2023.
      • Total company gross margin was 60%.
    • Exome and genome adjusted gross margin operated in excess of 65%.

    Operating expenses

    • Adjusted total operating expenses reduced to $45.4 million, a decrease of 26% year-over-year and 6% sequentially.
      • Total GAAP operating expenses were $50.1 million.

    Net loss

    • Adjusted net loss narrowed to $8.5 million, an improvement of 83% year-over-year and 52% sequentially.
      • GAAP net loss was $20.2 million.

    Cash burn and cash position

    • Total net use of cash was $17.2 million in the first quarter of 2024, an improvement of 71% year-over-year and 48% sequentially.
    • Cash, cash equivalents, marketable securities and restricted cash was $113.9 million as of March 31, 2024.
    1. Revenue and gross margin results from continuing operations, which we believe are representative of our ongoing business strategy exclude any revenue and cost of goods sold of the exited Legacy Sema4 diagnostic testing business for the current and all comparative periods. Total company results include GeneDx's continuing operations and the financial impacts of exited Legacy Sema4 business activities for the current and all comparative periods.
    2. Adjusted gross margin, adjusted total operating expenses and adjusted net loss are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.

    Updated GeneDx Full Year 2024 Guidance

    GeneDx has updated its full year 2024 guidance. Management expects GeneDx to:

    • Drive full year 2024 revenues between $235 and $245 million (previous guidance was $220 to $230 million);
    • Expand full year 2024 adjusted gross margin profile to at least 60% (previous guidance was at least 50%);
    • Use $70 to $80 million of net cash for full year 2024 (previous guidance was $75 to $80 million);
    • Turn profitable in 2025 (no change).

    First Quarter 2024 Business Highlights

    Driving sustainable growth and market leadership

    • Reached new milestone of sequencing 600k clinical exomes and genomes since inception, with over half sequenced since July 2021 and 100k sequenced since the fall. This continued acceleration of exome and genome sequencing and interpretation further solidifies GeneDx's industry leadership, enhances the robustness of its proprietary dataset, and enables more definitive diagnoses for more patients.
    • Presented new data at the American College of Medical Genetics and Genomics Annual Meeting further demonstrating the clinical superiority of exome compared to chromosomal microarray ("CMA"), supporting our efforts to eliminate the need for CMA to be ordered when exome is ordered first.
    • State Medicaid programs continue to expand coverage of rapid genetic testing in the neonatal intensive care unit ("NICU"), bringing total states covering rapid whole genome in the acute care setting to 11, including new coverage announced in:
      • Georgia (January 2024)
      • South Dakota (March 2024)
    • New York added outpatient whole exome sequencing ("WES") coverage to their Medicaid plan, effective April 1, 2024, bringing total states covering WES to 28.
    • Grew biopharma partner programs to 21, predominantly with biotech companies who are relying on us to find patients with a specific variant for clinical trial purposes.
    • Launched a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry, enabling improved access to genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment for biopharma partners.

    Webcast and Conference Call Details

    GeneDx will host a conference call today, April 29, 2024, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and our market opportunity, including our expected full year 2024 reported revenue guidance, our expectations regarding our adjusted gross margin profile in 2024, our use of net cash in 2024 and our turning profitable in 2025. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (vi) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 23, 2024 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

    About GeneDx

    At GeneDx (NASDAQ:WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

    Investor Relations Contact:

    [email protected]

    Media Contact:

    [email protected]

    Volume and revenue in the table below include the combination of the Legacy GeneDx diagnostic business with the data and information business of Legacy Sema4.

    Volume & Revenue

     1Q24 4Q23 3Q23 2Q23 1Q23
    Volumes         
    Whole exome, whole genome 16,592   15,663   13,216   11,855   8,705 
    Hereditary cancer 6,868   8,240   8,556   7,142   7,120 
    Other panels 31,763   33,692   35,861   35,931   36,953 
    Total 55,223   57,595   57,633   54,928   52,778 
              
    Revenue ($ millions)         
    Whole exome, whole genome$44.0  $39.2  $34.0  $28.7  $22.4 
    Hereditary cancer 5.5   5.5   4.5   3.8   4.3 
    Other panels 10.7   11.2   10.6   10.6   12.7 
    Data information 1.3   2.2   1.3   2.1   1.3 
    Total$61.5  $58.1  $50.4  $45.2  $40.7 
                        

    Unaudited Select Financial Information (in thousands)

     Three months ended March 31, 2024 Three months ended December 31, 2023
     GeneDx Legacy Sema4 Total GeneDx Legacy Sema4 Total
    Revenue$61,461  $961  $62,422  $58,107  $(689) $57,418 
    Adjusted cost of services 24,099   —   24,099   25,626   —   25,626 
    Adjusted gross profit (loss)$37,362  $961  $38,323  $32,481  $(689) $31,792 
    Adjusted gross margin % 60.8%  (100.0)%  61.4%  55.9%  100.0%  55.4%
                            



     Three months ended March 31, 2023
     GeneDx Legacy Sema4 Total
    Revenue$40,693  $2,446  $43,139 
    Adjusted cost of services 26,826   2,080   28,906 
    Adjusted gross profit (loss)$13,867  $366  $14,233 
    Adjusted gross margin % 34.1%  15.0%  33.0%
                



     Three months ended March 31, 2024
     Reported Depreciation and amortization Stock-based compensation expense Restructuring costs Change in FV of financial liabilities Charges related to business exit Other Adjusted
    Diagnostic test revenue$61,104  $—  $—  $—  $—  $—  $—  $61,104 
    Other revenue 1,318   —   —   —   —   —   —   1,318 
    Total revenue 62,422   —   —   —   —   —   —   62,422 
    Cost of services 25,011   (816)  (48)  (48)  —   —   —   24,099 
    Gross profit (loss) 37,411   816   48   48   —   —   —   38,323 
    Gross margin 59.9%              61.4%
    Research and development 11,567   (196)  187   (103)  —   —   —   11,455 
    Selling and marketing 16,085   (1,225)  20   (400)  —   —   —   14,480 
    General and administrative 22,445   (3,011)  292   (292)  —   —   —   19,434 
    Impairment loss —   —   —   —   —   —   —   — 
    Other, net 974   —   —   —   —   —   —   974 
    Loss from operations (13,660)  5,248   (451)  843   —   —   —   (8,020)
    Interest income (expense), net (597)  —   —   —   —   —   —   (597)
    Other income (expense), net (6,064)  —   —   —   6,101   —   —   37 
    Income tax benefit 82   —   —   —   —   —   —   82 
    Net loss$(20,239) $5,248  $(451) $843  $6,101  $—  $—  $(8,498)
                                    



     Three months ended March 31, 2023
     Reported Depreciation and amortization Stock-based compensation expense Restructuring costs Change in FV of financial liabilities Charges related to business exit Other Adjusted
    Diagnostic test revenue$41,850  $—  $—  $—  $—  $—    $41,850 
    Other revenue 1,289   —   —   —   —   —   —   1,289 
    Total revenue 43,139   —   —   —   —   —   —   43,139 
    Cost of services 27,903   (589)  1,666   (74)  —   —   —   28,906 
    Gross profit (loss) 15,236   589   (1,666)  74   —   —   —   14,233 
    Gross margin 35.3%              33.0%
    Research and development 14,592   (852)  (943)  (91)  —   —   —   12,706 
    Selling and marketing 13,452   (1,227)  (63)  (142)  —   —   —   12,020 
    General and administrative 43,689   (5,968)  (708)  (395)  —   —   —   36,618 
    Impairment loss 2,120   —   —   —   —   (2,120)  —   — 
    Other, net 1,747   —   —   —   —   —   —   1,747 
    Loss from operations (60,364)  8,636   48   702   —   2,120   —   (48,858)
    Interest income (expense), net (35)  —   —   —   —   —   —   (35)
    Other income (expense), net (737)  —   —   —   3,453   —   (2,750)  (34)
    Income tax benefit 147   —   —   —   —   —   —   147 
    Net loss$(60,989) $8,636  $48  $702  $3,453  $2,120  $(2,750) $(48,780)
                                    



     Three months ended December 31, 2023
     Reported Depreciation and amortization Stock-based compensation expense Restructuring costs Change in FV of financial liabilities Charges related to business exit Other Adjusted
    Diagnostic test revenue$55,214  $—  $—  $—  $—  $—  $—  $55,214 
    Other revenue 2,204   —   —   —   —   —   —   2,204 
    Total revenue 57,418   —   —   —   —   —   —   57,418 
    Cost of services 26,664   (915)  (123)  —   —   —   —   25,626 
    Gross profit (loss) 30,754   915   123   —   —   —   —   31,792 
    Gross margin 53.6%              55.4%
    Research and development 12,248   (919)  2,320   (1,300)  —   —   —   12,349 
    Selling and marketing 15,559   (1,225)  1,071   (487)  —   —   —   14,918 
    General and administrative 26,626   (3,035)  (2,356)  (197)  —   —   —   21,038 
    Impairment loss —   —   —   —   —   —   —   — 
    Other, net 1,964   —   —   —   —   (1,277)  —   687 
    Loss from operations (25,643)  6,094   (912)  1,984   —   1,277   —   (17,200)
    Interest income (expense), net (978)  —   —   —   —   —   —   (978)
    Other income (expense), net 437   —   —   —   (485)  —   48   — 
    Income tax benefit 411   —   —   —   —   —   —   411 
    Net loss$(25,773) $6,094  $(912) $1,984  $(485) $1,277  $48  $(17,767)
                                    



    GeneDx Holdings Corp.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share amounts)
     
     March 31, 2024 (Unaudited) December 31, 2023
    Assets:   
    Current assets:   
    Cash and cash equivalents$83,673  $99,681 
    Marketable securities 29,239   30,467 
    Accounts receivable 28,151   32,371 
    Due from related parties 772   445 
    Inventory, net 11,615   8,777 
    Prepaid expenses and other current assets 9,974   10,598 
    Total current assets 163,424   182,339 
    Operating lease right-of-use assets 26,304   26,900 
    Property and equipment, net 31,301   32,479 
    Intangible assets, net 169,119   172,625 
    Other assets (1) 4,380   4,413 
    Total assets$394,528  $418,756 
    Liabilities and Stockholders' Equity:   
    Current liabilities:   
    Accounts payable and accrued expenses$32,410  $37,456 
    Due to related parties 1,041   1,379 
    Short-term lease liabilities 4,043   3,647 
    Other current liabilities 13,240   16,336 
    Total current liabilities 50,734   58,818 
    Long-term debt, net of current portion 52,293   52,688 
    Long-term lease liabilities 62,030   62,938 
    Other liabilities 20,836   14,735 
    Deferred taxes 1,418   1,560 
    Total liabilities 187,311   190,739 
    Stockholders' Equity:   
    Preferred stock —   — 
    Class A common stock 2   2 
    Additional paid-in capital 1,527,351   1,527,778 
    Accumulated deficit (1,320,427)  (1,300,188)
    Accumulated other comprehensive income 291   425 
    Total stockholders' equity 207,217   228,017 
    Total liabilities and stockholders' equity$394,528  $418,756 



    (1)Other assets includes $987 thousand of restricted cash as of both March 31, 2024 and December 31, 2023.
      



    GeneDx Holdings Corp.

    Condensed Consolidated Statements of Operations (Unaudited)

    (in thousands, except share and per share amounts)
     
     Three months ended March 31,
     2024 2023
    Revenue   
    Diagnostic test revenue$61,104  $41,850 
    Other revenue 1,318   1,289 
    Total revenue 62,422   43,139 
    Cost of services 25,011   27,903 
    Gross profit 37,411   15,236 
    Research and development 11,567   14,592 
    Selling and marketing 16,085   13,452 
    General and administrative 22,445   43,689 
    Impairment loss —   2,120 
    Other operating expenses, net 974   1,747 
    Loss from operations (13,660)  (60,364)
        
    Non-operating income (expenses), net   
    Change in fair value of warrants and earn-out contingent liabilities (6,101)  (3,453)
    Interest expense, net (597)  (35)
    Other income, net 37   2,716 
    Total non-operating loss, net (6,661)  (772)
    Loss before income taxes$(20,321) $(61,136)
    Income tax benefit 82   147 
    Net loss$(20,239) $(60,989)
        
    Weighted average shares outstanding of Class A common stock 26,062,170   20,061,945 
    Basic and diluted net loss per share, Class A common stock$(0.78) $(3.04)
            



    GeneDx Holdings Corp.

    Condensed Consolidated Statements of Cash Flows (Unaudited)

    (in thousands)
     
     Three months ended March 31,
     2024 2023
    Operating activities   
    Net loss$(20,239) $(60,989)
    Adjustments to reconcile net loss to net cash used in operating activities:   
    Depreciation and amortization expense 5,248   8,636 
    Stock-based compensation expense (451)  48 
    Change in fair value of warrants and contingent liabilities 6,101   3,453 
    Deferred tax benefit (82)  (147)
    Provision for excess and obsolete inventory 40   — 
    Change in third party payor reserves (193)  (1,070)
    Gain on debt forgiveness —   (2,750)
    Impairment loss —   2,120 
    Other 846   274 
    Change in operating assets and liabilities:   
    Accounts receivable 4,220   9,723 
    Inventory (2,877)  1,331 
    Accounts payable and accrued expenses (4,733)  (13,400)
    Other assets and liabilities (4,293)  (2,789)
    Net cash used in operating activities (16,413)  (55,560)
    Investing activities   
    Purchases of property and equipment (443)  — 
    Purchases of marketable securities (5,167)  — 
    Proceeds from sales of marketable securities 598   — 
    Proceeds from maturities of marketable securities 5,855   — 
    Development of internal-use software assets —   (462)
    Net cash provided by (used in) investing activities 843   (462)
    Financing activities   
    Proceeds from offerings, net of issuance costs —   135,439 
    Exercise of stock options 24   266 
    Long-term debt principal payments —   (2,000)
    Finance lease payoff and principal payments (462)  (1,047)
    Net cash (used in) provided by financing activities (438)  132,658 
    Net (decrease) increase in cash, cash equivalents and restricted cash (16,008)  76,636 
    Cash, cash equivalents and restricted cash, at beginning of period 100,668   138,303 
    Cash, cash equivalents and restricted cash, at end of period (1)$84,660  $214,939 
        
    Supplemental disclosures of cash flow information   
    Cash paid for interest$2,019  $583 
    Cash paid for taxes$300  $104 
    Purchases of property and equipment in accounts payable and accrued expenses$36  $1,073 
    Software development costs in accounts payable and accrued expenses$—  $157 



    (1)Cash, cash equivalents and restricted cash at March 31, 2024 excludes marketable securities of $29.2 million.
      



    Primary Logo

    Get the next $WGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GeneDx Announces Completion of Fabric Genomics Acquisition

      Closing unlocks the next phase of genomic medicine, enabling an end-to-end centralized and decentralized model for offering clinically-actionable genomic insights at a global scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powered by centralized intelligence to set the standard of care across the globe. "Healthcare is at an inflection point where genomic insights must be integrated into standar

      5/7/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

      Combining GeneDx's industry-leading rare disease data asset and Fabric Genomics' AI-powered platform furthers the Company's leadership and creates an unrivaled platform to deliver global access to genomic information Accelerates the NICU, enables newborn screening, and opens global market opportunities with on-site sequencing and decentralized interpretation GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction enables GeneDx's leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence. "H

      4/16/25 6:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by GeneDx Holdings Corp.

      DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:34:16 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form DEF 14A filed by GeneDx Holdings Corp.

      DEF 14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:33:10 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by GeneDx Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 7:04:19 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Meister Keith A. was granted 434,848 shares (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/6/25 9:45:05 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Director Pfenniger Richard C Jr converted options into 918 shares, increasing direct ownership by 3% to 28,582 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/5/25 4:48:43 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 753 shares, sold $43,879 worth of shares (388 units at $113.09) and was granted 420 shares, increasing direct ownership by 26% to 3,757 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/1/25 7:46:17 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on GeneDx with a new price target

      Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00

      8/28/24 7:58:09 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Craig Hallum initiated coverage on GeneDx with a new price target

      Craig Hallum initiated coverage of GeneDx with a rating of Buy and set a new price target of $43.00

      7/10/24 8:09:23 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Jefferies resumed coverage on GeneDx with a new price target

      Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00

      6/3/24 8:54:48 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    See more
    • GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

      Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

      1/2/25 4:01:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

      Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

      11/18/24 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      6/5/24 8:45:06 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $842,604 worth of shares (40,000 units at $21.07) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/31/24 5:37:30 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $3,424,989 worth of shares (170,000 units at $20.15) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/28/24 8:40:42 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      4/8/25 8:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/20/24 9:36:13 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/19/24 8:00:24 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/8/24 5:23:34 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology